Kirrhos Pharmaceuticals is Pharmaceuticals in United States that focus on disease indications business. Founded in 2019. They cover business area such as developer, inhibitor drug, nonalcoholic steatohepatitis, an oral medicine, a severe form, non-alcoholic fatty liver disease, treatment, fibrotic disease indication, such pulmonary fibrosis, kidney fibrosis, potentially cancer, healthcare professional.
2019
( 5 years old in 2024 )
Disease Indications
-
840 Research Parkway
Suite 250
Oklahoma City, OK 73107
United States
Private
developerinhibitor drugnonalcoholic steatohepatitisan oral medicinea severe formnon-alcoholic fatty liver diseasetreatmentfibrotic disease indicationsuch pulmonary fibrosiskidney fibrosispotentially cancerhealthcare professional
* We use standard office opening hours in near Kirrhos Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Kirrhos Pharmaceuticals is Pharmaceuticals business from United States that founded in 2019 (5 years old in 2024), Kirrhos Pharmaceuticals business is focusing on Disease Indications.
Kirrhos Pharmaceuticals headquarter office and corporate office address is located in 840 Research Parkway Suite 250 Oklahoma City, OK 73107 United States.
Kirrhos Pharmaceuticals was founded in United States.
In 2024, Kirrhos Pharmaceuticals is currently focus on disease indications sector.
Above is snippet of Google Trends for "disease indications" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Kirrhos Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
